Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice

Future Oncol. 2022 Jul 12. doi: 10.2217/fon-2022-0122. Online ahead of print.

Abstract

Aim: To evaluate the significance of next-generation sequencing-based gene panel testing in surgically resectable colorectal cancer by analyzing real-world data. Materials & methods: A total of 107 colorectal cancer patients who underwent curative surgery were included, and correlations between next-generation sequencing data and clinicopathological findings were evaluated. Results: More combination patterns in gene alteration were identified in advanced-stage tumors than in early-stage tumors. The copy number alteration count was significantly lower in right-sided colon tumors and early-stage tumors. Homologous recombination deficiency was more often identified in advanced-stage tumors, and high homologous recombination deficiency status was useful for identifying high-risk stage II tumors. Conclusion: Homologous recombination deficiency was identified as a useful result of gene panel testing with novel utility in clinical practice.

Keywords: colorectal cancer; copy number alterations; homologous recombination deficiency; next-generation sequencing; tumor mutational burden.